Apimeds Pharmaceuticals US
Developing a bee-venom knee-osteoarthritis therapy and Bitcoin-treasury infrastructure.
Something off on this page? Send us feedback.
Profile
Develops Apitox, a purified bee-venom biologic for knee-osteoarthritis pain, while building MindWave's institutional Bitcoin-treasury and blockchain services. Both segments were pre-revenue in the latest disclosures, with clinical approval and third-party financial infrastructure central to commercialization.
Pairs a clinical-stage biologic with a digital-asset treasury and blockchain-platform business. The BioBusiness segment develops Apitox, a purified honeybee-venom injection proposed for knee-osteoarthritis pain and inflammation. The Digital Assets segment, through MindWave, is developing corporate Bitcoin treasury controls, yield programs, validator services and risk-monitoring tools.
Runs its executive office from Matawan, New Jersey; the digital-asset operation is headquartered in Singapore and includes an operation in the United Arab Emirates. U.S. Apitox rights and historical data come from Apimeds Korea, which retains proprietary analytical and manufacturing methods and receives a perpetual royalty.
Neither segment had generated revenue in the latest disclosures. Apitox needs a successful late-stage trial and FDA approval; planned digital services depend on regulated custodians and other infrastructure partners because direct custody, execution and intermediation are not licensed operations.
Company facts
Key statistics
Year to date −76.8% · Average volume (30d) 142.5K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | — | −$11.77 | — | — | — | — | −3.19% |
| May 26, 2026Q1 FY26 | — | −$22.60 | — | — | — | — | 0.00% |
| Nov 12, 2025Q3 FY25 | — | −$0.14 | — | — | — | — | +4.10% |
| Aug 19, 2025Q2 FY25 | — | −$0.26 | — | — | — | — | −4.74% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$20.0K | $0 | |
| Operating income | −$364.4K | −$2.7M | −$1.8M | −$7.0M | −$4.1M | −$6.3M | |
| Net income | −$402.4K | −$2.7M | −$1.8M | −$1.2M | −$35.1M | −$20.2M | |
| Diluted EPS | −$3.48 | −$26.00 | −$14.00 | −$0.92 | −$22.60 | −$11.77 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $278.4K · Total debt $14.6M · Total assets $127.6M · Shareholders' equity $106.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.51M · Float 563.2K · 37.3% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Coinbase
Institutional custody, trading and staking platform overlap.
- BitGo
Institutional custody and wallet infrastructure for treasury users.
- Pacira BioSciences
FDA-approved knee-OA injection for non-opioid pain treatment.
- Anika Therapeutics
Viscosupplement injections for the U.S. knee-OA pain market.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US | $3.87 | −0.26% | $5.9M | — | — | — | — |
| Coinbase | $178.50 | −0.02% | $47.13B | — | 206.3 | 8.5 | −18.5% |
| BitGo | $6.90 | +0.53% | $734.7M | — | 310.8 | 0.0 | — |
| Pacira BioSciences | $25.76 | 0.00% | $1.01B | 73.3 | 8.3 | 1.4 | +6.2% |
| Anika Therapeutics | $21.10 | −0.50% | $282.4M | — | 34.5 | 2.3 | +15.6% |
| Median | 73.3 | 120.4 | 1.8 | +6.2% |